I-191(Cat No.:I019193) is a potent and selective antagonist of Protease-Activated Receptor 2 (PAR2), a G protein-coupled receptor that is involved in a variety of physiological and pathological processes, including inflammation, pain, and cancer. By inhibiting the activity of PAR2, I-191 can block the signaling pathways that lead to inflammation and pain. I-191 has shown promising results in preclinical studies as a potential therapy for inflammatory bowel disease, cancer, and other PAR2-mediated diseases. It has been found to reduce inflammation and tumor growth in animal models of these diseases. I-191 is currently undergoing further studies to evaluate its safety and efficacy in humans.
| Catalog Number | I019193 |
| CAS Number | 1690172-25-8 |
| Molecular Formula | C₂₃H₂₆FN₅O₂ |
| Purity | ≥95% |
| IUPAC Name | 4-[8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazin-2-one |
| InChI | InChI=1S/C23H26FN5O2/c1-22(2,3)16-12-17(14-6-8-15(24)9-7-14)27-29-13-18(26-19(16)29)20(30)28-11-10-25-21(31)23(28,4)5/h6-9,12-13H,10-11H2,1-5H3,(H,25,31) |
| InChIKey | DTASTQAQBOZSRR-UHFFFAOYSA-N |
| SMILES | CC1(C(=O)NCCN1C(=O)C2=CN3C(=N2)C(=CC(=N3)C4=CC=C(C=C4)F)C(C)(C)C)C |
| Reference | [1]. Jiang Y, et al. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J Pharmacol Exp Ther. 2018 Feb;364(2):246-257. |
